Biosimilars Education: Oncobiologics/Premier Deal Aims To Boost Adoption, Data Collection
This article was originally published in The Pink Sheet Daily
Executive Summary
With two biosimilars set to move into Phase III this year, Oncobiologics hopes partnership with hospital services firm Premier will generate 'best practices around the optimal use of these cost-effective treatments.'
You may also be interested in...
Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start
Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?
Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start
Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?
Biosimilar Pathway Quickly Becoming Crowded In U.S.
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.